

Shield Therapeutics plc
("Shield" or the "Group" or the "Company")

2019 Annual Report and 2020 AGM Notice

London, UK, 22 May 2020: Shield Therapeutics plc (LSE: STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru[®]/Accrufer[®] (ferric maltol), a novel oral iron treatment, announces that the following documents have now been sent to shareholders:

- Annual Report and Accounts for the year ended 31 December 2019
- Notice of Annual General Meeting ("AGM") 2020

In accordance with AIM Rule 26, these documents are also available to view on the Company's website www.shieldtherapeutics.com/investors/corporate-documents/.

The AGM is scheduled to be held at 1.00pm BST on Thursday 18 June 2020. Due to COVID-19 and the latest "stay at home" restrictions, this meeting will be held virtually, and attendance will be available online and telephonically.

The Company will provide a facility for shareholders to join the AGM online and telephonically and there will be an opportunity for shareholders to ask questions. In order to facilitate the process, the Board would request that shareholders register for the meeting and submit questions in advance, before 5.00pm (BST) on 16 June 2020.

To register for dial-in details and to submit any questions please contact Walbrook PR via email at shield@walbrookpr.com or call +44 (0)20 7933 8787.

For further information please contact:

Shield Therapeutics plc

Tim Watts, CEO
Karen Chandler Smith, Investor Relations

www.shieldtherapeutics.com

+44 (0)20 7186 8500

Nominated Adviser and Joint Broker

Peel Hunt LLP

James Steel/Dr Christopher Golden

+44 (0)20 7418 8900

Joint Broker

finnCap Ltd

Geoff Nash/Matt Radley/Alice Lane

+44 (0)20 7220 0500

Financial PR & IR Advisor

Walbrook PR

Paul McManus/Lianne Cawthorne

+44 (0)20 7933 8780 or shield@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7584 391 303

About Shield Therapeutics plc

Shield is a de-risked, commercial stage, specialty pharmaceutical company delivering innovative pharmaceuticals to address patients' unmet medical needs. The Company's clear purpose is to develop products that help patients become people again, enabling them to enjoy the things that make a difference in their everyday lives. The Group's lead product, Feraccru[®]/ Accrufer[®] has exclusive IP rights until the mid-2030s and is approved for the treatment of iron deficiency with or without anaemia in adults in the European Union, the United States and Switzerland. In Europe it is marketed as Feraccru[®] with commercialisation led by Norgine BV and in the USA the product will be marketed as Accrufer[®] with Shield currently in the process of selecting a commercialisation partner. Shield also has an exclusive licence agreement with Beijing Aosaikang Pharmaceutical Co. Ltd for the development and commercialisation of Feraccru[®]/Accrufer[®] in China, Hong Kong, Macau and Taiwan. For more information please visit www.shieldtherapeutics.com

About Feraccru[®]/Accrufer[®]

Feraccru[®]/Accrufer[®] is a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia that has been shown to be an efficacious and well-tolerated therapy in a range of controlled phase 3 trials, and offers a compelling alternative to IV iron for those patients unable to tolerate salt-based oral iron therapies and wish to avoid the complexities of infusion-based iron therapies.

When salt-based oral iron therapies are ingested they can cause a range of mild-to-severe gastrointestinal tract (GI) adverse events, including nausea, bloating and constipation through the release and subsequent reactivity of free iron in the GI tract, leading to poor tolerability, reduced patient compliance and ultimately treatment failure. Feraccru[®]/Accrufer[®] is not an iron salt and, as a result, it does not routinely cause the same treatment-limiting intolerance issues of salt-based iron therapies, whilst the iron from the ferric maltol molecule can be readily absorbed.

Prior to Feraccru[®]/Accrufer[®], IV iron therapies were the only realistic alternative treatment option for iron deficient patients with or without anaemia intolerant of or unwilling to be treated salt-based oral iron therapies. However, use of such an invasive, costly, inconvenient and complex to administer treatment option, which is associated with potentially life-threatening and spontaneous hypersensitivity reactions, means there remains a clear unmet medical need for these patients to have access to an effective therapy that is well tolerated, convenient and does not require hospital-based administration. Feraccru[®]/Accrufer[®] meets those requirements.

About Iron Deficiency

The WHO states that iron deficiency is the most common and widespread nutritional disorder in the world. As well as affecting a large number of women and children in non-industrialized countries, it is the only nutrient deficiency which is also significantly prevalent in virtually all industrialised nations. There are no current global figures for iron deficiency but, using anaemia as an indirect indicator, it can be estimated that most preschool children and pregnant women in non-industrialised countries, together with at least 30-40% in industrialized countries, are iron deficient.